Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.90
+0.18000.06%
Post-market: 311.900.00000.00%19:30 EDT
Volume:151.52K
Turnover:47.21M
Market Cap:18.77B
PE:33.86
High:313.00
Open:312.74
Low:310.31
Close:311.72
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.85
T/O Rate:0.25%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.51

Loading ...

Ingenia Therapeutics Expects USD 5 Million MK-8748 Milestone Payment from Merck Unit Eyebiotech

Reuters
·
Sep 28

Press Release: 111, Inc. Announces Establishment of the Special Committee

Dow Jones
·
Sep 28

Ain Holdings Responds to Supreme Court Ruling on Former Directors with Stronger Compliance Push

TIPRANKS
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

Talius strengthens sales leadership with healthcare tech executive hire

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

US FDA Approves AbbVie's Drug for Parkinson's Disease

Reuters
·
Sep 26

US FDA - Approves Juvmo (Tavapadon) for Parkinson’s Disease in Adults on Sept 25, 2026

THOMSON REUTERS
·
Sep 26

Ifinatamab Deruxtecan Biologics License Application for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters
·
Sep 26

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

Nordhealth Insider Boosts Stake in Cloud Healthcare SaaS Provider

TIPRANKS
·
Sep 26